Phosphodiesterase 5 inhibitors: preclinical and early-phase breakthroughs for impotence treatments

References

• Ayta IA, McKinlay JB, Krane RJ. The likely worldwide increase in erectile dysfunction between 1995 and 2025 and some possible policy consequences. BJU Int. 1999 Jul;84(1):50–56. doi: 10.1046/j.1464-410x.1999.00142.x
   PubMed Web of Science ®Google Scholar
• Smith WB, McCaslin IR, Gokce A, et al. PDE5 inhibitors: considerations for preference and long-term adherence. Int J Clin Pract. 2013 Aug;67(8):768–780.
   PubMed Web of Science ®Google Scholar
• Gul M, Serefoglu EC. An update on the drug safety of treating erectile dysfunction. Expert Opin Drug Saf. 2019 Oct;18(10):965–975. doi: 10.1080/14740338.2019.1659244
   PubMed Web of Science ®Google Scholar
• Skeith L, Yamashita C, Mehta S, et al. Sildenafil and furosemide associated ototoxicity: consideration of drug-drug interactions, synergy, and broader clinical relevance. J Popul Ther Clin Pharmacol. 2013;20(2):e128–31.
   PubMedGoogle Scholar
• Hellstrom WJ, Overstreet JW, Yu A, et al. Tadalafil has no detrimental effect on human spermatogenesis or reproductive hormones. J Urol. 2003 Sep;170(3):887–891.
   PubMed Web of Science ®Google Scholar
• Peak TC, Yafi FA, Sangkum P, et al. Emerging drugs for the treatment of erectile dysfunction. Expert Opin Emerg Drugs. 2015 Jun;20(2):263–275. doi: 10.1517/14728214.2015.1021682.
   PubMed Web of Science ®Google Scholar
• Cho MC, Paick JS. Udenafil for the treatment of erectile dysfunction. Ther Clin Risk Manag. 2014;10:341–354. doi: 10.2147/TCRM.S39727
   PubMed Web of Science ®Google Scholar
• Kim BH, Lim HS, Chung JY, et al. Safety, tolerability and pharmacokinetics of udenafil, a novel PDE-5 inhibitor, in healthy young Korean subjects. Br J Clin Pharmacol. 2008 Jun;65(6):848–854.
   PubMed Web of Science ®Google Scholar
• Paick JS, Kim SW, Park YK, et al. ORIGINAL RESEARCH—ED PHARMACOTHERAPY: The Efficacy and Safety of Udenafil [Zydena] for the Treatment of Erectile Dysfunction in Hypertensive Men Taking Concomitant Antihypertensive Agents. J Sex Med. 2009 Nov;6(11):3166–3176.
   PubMed Web of Science ®Google Scholar
• Paick JS, Kim SW, Yang DY, et al. The efficacy and safety of udenafil, a new selective phosphodiesterase type 5 inhibitor, in patients with erectile dysfunction. J Sex Med. 2008 Apr;5(4):946–953.
   PubMed Web of Science ®Google Scholar
• Park HJ, Park JK, Park K, et al. Efficacy of udenafil for the treatment of erectile dysfunction up to 12 hours after dosing: a randomized placebo-controlled trial. J Sex Med. 2010 Jun;7(6):2209–2216.
   PubMed Web of Science ®Google Scholar
• Zhao C, Kim SW, Yang DY, et al. Efficacy and safety of once-daily dosing of udenafil in the treatment of erectile dysfunction: results of a multicenter, randomized, double-blind, placebo-controlled trial. Eur Urol. 2011 Aug;60(2):380–387.
   PubMed Web of Science ®Google Scholar
• Moon KH, Kim SW, Moon DG, et al. A Phase 3 Study to Evaluate the 1-Year Efficacy and Safety of Udenafil 75 mg Once Daily in Patients with Erectile Dysfunction. J Sex Med. 2016 Aug;13(8):1263–1269. doi: 10.1016/j.jsxm.2016.05.011.
   PubMed Web of Science ®Google Scholar
• Chung JH, Kwon TG, Kwak C, et al. Efficacy and Safety of Udenafil Once Daily in Patients with Erectile Dysfunction after Bilateral Nerve-Sparing Robot-Assisted Laparoscopic Radical Prostatectomy: A Randomized, Double-Blind, Placebo-Controlled Study. World J Mens Health. 2023 Jul;41(3):612–622.
   PubMedGoogle Scholar
• Kouvelas D, Goulas A, Papazisis G, et al. PDE5 inhibitors: in vitro and in vivo pharmacological profile. Curr Pharm Des. 2009;15(30):3464–3475. doi: 10.2174/138161209789206971
   PubMed Web of Science ®Google Scholar
• Salem EA, Kendirci M, Hellstrom WJ. Udenafil, a long-acting PDE5 inhibitor for erectile dysfunction. Curr Opin Invest Drugs. 2006 Jul;7(7):661–669.
   PubMedGoogle Scholar
• Chung JH, Kang DH, Oh CY, et al. Safety and efficacy of once daily administration of 50 mg mirodenafil in patients with erectile dysfunction: a multicenter, double-blind, placebo controlled trial. J Urol. 2013 Mar;189(3):1006–1013.
   PubMed Web of Science ®Google Scholar
• Lee J, Yoo HH, Rhim KJ, et al. Metabolism and excretion of 5-ethyl-2-{5-[4-(2-hydroxyethyl)piperazine-1-sulfonyl]-2-propoxyphenyl}-7-propyl-3,5-dihydropyrrolo[3,2-d]-pyrimidin-4-one (SK3530) in rats. Rapid Commun Mass Spectrom. 2007;21(7):1139–1149. doi: 10.1002/rcm.2943
   PubMed Web of Science ®Google Scholar
• Sun H, Wang J, Sun Y, et al. Rapid and sensitive liquid chromatography with tandem mass spectrometry method for the simultaneous quantification of yonkenafil and its major metabolites in rat plasma. J Sep Sci. 2016 Oct;39(19):3700–3708.
   PubMed Web of Science ®Google Scholar
• Prince WT, Campbell AS, Tong W, et al. SLX-2101, a new long-acting PDE5 inhibitor: preliminary safety, tolerability, PK and endothelial function effects in healthy subjects. J Urol. 2006;175(4S):299–300. doi: 10.1016/S0022-5347(18)33160-4
   Google Scholar
• Huang SA, Lie JD. Phosphodiesterase-5 (PDE5) Inhibitors in the Management of Erectile Dysfunction. P T. 2013 Jul;38(7):407–419.
   PubMedGoogle Scholar
• Bruzziches R, Francomano D, Gareri P, et al. An update on pharmacological treatment of erectile dysfunction with phosphodiesterase type 5 inhibitors. Expert Opin Pharmacother. 2013 Jul;14(10):1333–1344.
   PubMed Web of Science ®Google Scholar
• Palit V, Eardley I. An update on new oral PDE5 inhibitors for the treatment of erectile dysfunction. Nat Rev Urol. 2010 Nov;7(11):603–609. doi: 10.1038/nrurol.2010.165
   PubMed Web of Science ®Google Scholar
• Kim TE, Kim BH, Kim JR, et al. Effect of food on the pharmacokinetics of the oral phosphodiesterase 5 inhibitor udenafil for the treatment of erectile dysfunction. Br J Clin Pharmacol. 2009 Jul;68(1):43–46.
   PubMed Web of Science ®Google Scholar
• Forgue ST, Patterson BE, Bedding AW, et al. Tadalafil pharmacokinetics in healthy subjects. Br J Clin Pharmacol. 2006 Mar;61(3):280–288.
   PubMed Web of Science ®Google Scholar
• Kang KK, Yu JY, Yoo M, et al. The effect of DA-8159, a novel PDE5 inhibitor, on erectile function in the rat model of hypercholesterolemic erectile dysfunction. Int J Impot Res. 2005;17(5):409–416. doi: 10.1038/sj.ijir.3901331
   PubMed Web of Science ®Google Scholar
• Park HJ, Moon KH, Lee SW, et al. Mirodenafil for the treatment of erectile dysfunction: a systematic review of the literature. World J Mens Health. 2014 Apr;32(1):18–27. doi: 10.5534/wjmh.2014.32.1.18.
   PubMedGoogle Scholar
• Paick JS, Ahn TY, Choi HK, et al. ORIGINAL RESEARCH—ED PHARMACOTHERAPY: Efficacy and Safety of Mirodenafil, a New Oral Phosphodiesterase Type 5 Inhibitor, for Treatment of Erectile Dysfunction. J Sex Med. 2008 Nov;5(11):2672–2680.
   PubMed Web of Science ®Google Scholar
• Bang WJ, Oh CY, Yoo C, et al. Efficacy and safety of the simultaneous administration of mirodenafil and an α-blocker in men with BPH-LUTS: a multicenter open-label prospective study. Int J Impot Res. 2013;25(4):149–154. doi: 10.1038/ijir.2012.44
   PubMed Web of Science ®Google Scholar
• Paick JS, Kim JJ, Kim SC, et al. Efficacy and safety of mirodenafil in men taking antihypertensive medications. J Sex Med. 2010 Sep;7(9):3143–3152.
   PubMed Web of Science ®Google Scholar
• Lee HS, Park EJ, Ji HY, et al. Identification of cytochrome P450 enzymes responsible for N -dealkylation of a new oral erectogenic, mirodenafil. Xenobiotica. 2008 Jan;38(1):21–33.
   PubMed Web of Science ®Google Scholar
• Liang B, Wang J, Bai N, et al. Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Oral Doses of Youkenafil Hydrochloride, a Phosphodiesterase Type 5 Inhibitor, in Healthy Chinese Male Volunteers. Clin Pharmacol Drug Dev. 2022 Oct;11(10):1184–1190. doi: 10.1002/cpdd.1108.
   PubMed Web of Science ®Google Scholar
• Alshehri YM, Al-Majed AA, Attwa MW, et al. Lodenafil. Profiles Drug Subst Excip Relat Methodol. 2022;47:113–147.
   Google Scholar
• Glina S, Toscano I, Gomatzky C, et al. Efficacy and tolerability of lodenafil carbonate for oral therapy in erectile dysfunction: a phase II clinical trial. J Sex Med. 2009 Feb;6(2):553–557.
   PubMed Web of Science ®Google Scholar
• Glina S, Fonseca GN, Bertero EB, et al. ORIGINAL RESEARCH—ED PHARMACOTHERAPY: Efficacy and Tolerability of Lodenafil Carbonate for Oral Therapy of Erectile Dysfunction: A Phase III Clinical Trial. J Sex Med. 2010 May;7(5):1928–1936.
   PubMed Web of Science ®Google Scholar
• Albersen M, Shindel AW, Mwamukonda KB, et al. The future is today: emerging drugs for the treatment of erectile dysfunction. Expert Opin Emerg Drugs. 2010 Sep;15(3):467–480.
   PubMed Web of Science ®Google Scholar
• Toque HA, Teixeira CE, Lorenzetti R, et al. Pharmacological characterization of a novel phosphodiesterase type 5 (PDE5) inhibitor lodenafil carbonate on human and rabbit corpus cavernosum. Eur J Pharmacol. 2008 Sep 4;591(1–3):189–195. doi: 10.1016/j.ejphar.2008.06.055
   PubMed Web of Science ®Google Scholar
• BioSpace. Surface Logix reports data on SLX-2101 for erectile dysfunction at the American Urological Association meeting. BioSpace 2006. (Accessed Mar 3, 2023). https://www.biospace.com/article/releases/surface-logix-reports-data-on-slx-2101-for-erectile-dysfunction-at-the-american-urological-association-meeting-/.
   Google Scholar
• Kim S, Cho MC, Cho SY, et al. Novel Emerging Therapies for Erectile Dysfunction. World J Mens Health. 2021 Jan;39(1):48–64.
   PubMedGoogle Scholar
• Ismail EA, El-Sakka AI. Innovative trends and perspectives for erectile dysfunction treatment: A systematic review. Arab J Urol. 2016;14(2):84–93. doi: 10.1016/j.aju.2016.04.002
   PubMed Web of Science ®Google Scholar